Recruiting
Phase 1

BHV-1400

Sponsor:

Biohaven Therapeutics Ltd.

Code:

NCT07054684

Conditions

IgA Nephropathy

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

BHV-1400

Study Details

Brief summary:

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).

Conditions

IgA Nephropathy

Study ID

NCT07054684

Start date

Jul 30, 2025

Status verified date

Jun, 2026

Completion date

Jul, 2027

Anticipated

Primary completion date

Jul, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Key Inclusion Criteria:

1\. Participants must have biopsy-confirmed IgA Nephropathy

Key Exclusion Criteria:

1. Any secondary IgAN
2. Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: BHV-1400

Interventions

BHV-1400

BHV-1400 is delivered subcutaneously (SC)

Primary outcome measure

  • Number of participants with Serious AEs (SAEs), AEs leading to discontinuation, deaths [ Time Frame: Up to 1 year ]
  • Number of participants with Grade 3-4 treatment-emergent laboratory abnormalities [ Time Frame: Up to 1 year ]

Central Contacts and Locations

Central contacts

Chief Medical Officer

203-404-0410clinicaltrials@biohavenpharma.com

Locations

Site-001

Recruiting

Farmington, Connecticut, United States, 06030

Site-003

Recruiting

Miami Lakes, Florida, United States, 33016

Site-011

Recruiting

Miami Lakes, Florida, United States, 33172

Site-013

Recruiting

Orlando, Florida, United States, 32806

Site-005

Recruiting

Pembroke Pines, Florida, United States, 33029

Site-008

Recruiting

Lawrenceville, Georgia, United States, 30046

Site-009

Recruiting

Hinsdale, Illinois, United States, 60521

Site-012

Recruiting

Indianapolis, Indiana, United States, 46268

Site-015

Recruiting

Shelby, Michigan, United States, 48316

Site-006

Recruiting

Chesterfield, Missouri, United States, 63017

Site-002

Recruiting

Dakota Dunes, South Dakota, United States, 57049

Site-014

Recruiting

Houston, Texas, United States, 77027

Site-004

Recruiting

Houston, Texas, United States, 77099

Site-016

Recruiting

Salt Lake City, Utah, United States, 84115

More Information

Sponsor

Biohaven Therapeutics Ltd.

Last update posted

Jun 23, 2026

Last verified

Jun, 2026

Keywords

  • IgAN
  • proteinuria
  • glomerulonephropathy
  • chronic kidney disease
  • kidney disease
  • CKD
  • nephritis
  • urologic disease
  • glomerulonephritis
  • Glomerular disease
  • Iga nephropathy
  • renal disease

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Biohaven Therapeutics Ltd. on 2026-06-23.